Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Could the future of immunotherapy in HR+ breast cancer depend more on patient selection than the drug itself?
SACI-IO HR+ evaluated:
- Sacituzumab Govitecan + Pembrolizumab
- Sacituzumab Govitecan
HR+/HER2− metastatic breast cancer
- Endocrine therapy pretreated
- 0-1 prior chemotherapy for metastatic disease
- No prior TOP1 ADC or PD-(L)1 inhibitor
Primary endpoint: PFS
Overall population:
- PFS: 8.4 vs 6.7 mo, HR 0.76, p=0.12
- OS: 20.0 vs 18.0 mo, HR 0.74
ORR: 28.8% vs 19.2%
PD-L1 CPS ≥1 subgroup (44%):
- PFS: 11.1 vs 5.6 mo, HR 0.51
- OS: 18.5 vs 12.5 mo, HR 0.59
DOR: 12.9 vs 4.5 mo
Grade ≥3 TEAEs: 76.9% vs 69.2%
No new safety signals.
Verdict:
Formally negative. But a 5.5-month PFS improvement and 6-month OS improvement in PD-L1-positive disease is hard to ignore. Maybe the challenge is not finding the right combination. Maybe it’s finding the right patient.”
Other articles featuring Rishabh Jain on OncoDaily.